Jiangxi has introduced an innovative working capital system and established a direct settlement model for advance payments and hospital refunds, effectively cutting the settlement cycle for pharmaceutical enterprises from 180 days to just 30 days. This substantial reduction has markedly enhanced the efficiency of enterprise capital operations. Since the implementation of direct settlement for centrally procured drugs and consumables in 2020, and the subsequent expansion of this practice to include nationally negotiated drugs in December 2024, Jiangxi has, as of July 2025, cumulatively settled payments totaling 29.642 billion yuan. By refining the working capital system, optimizing settlement processes, and bolstering fund management, Jiangxi has achieved comprehensive coverage of direct medical insurance settlement for both centrally procured and nationally negotiated drugs and consumables, thereby ensuring the security and efficiency of the entire settlement process.